These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7819069)
1. Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells. Su GM; Davey MW; Davey RA; Kidman AD Br J Haematol; 1994 Nov; 88(3):566-74. PubMed ID: 7819069 [TBL] [Abstract][Full Text] [Related]
2. Extended multidrug resistance in haemopoietic cells. Marks DC; Su GM; Davey RA; Davey MW Br J Haematol; 1996 Dec; 95(4):587-95. PubMed ID: 8982031 [TBL] [Abstract][Full Text] [Related]
3. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Davey RA; Longhurst TJ; Davey MW; Belov L; Harvie RM; Hancox D; Wheeler H Leuk Res; 1995 Apr; 19(4):275-82. PubMed ID: 7752673 [TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Takeshita A; Shinjo K; Naito K; Ohnishi K; Sugimoto Y; Yamakawa Y; Tanimoto M; Kitamura K; Naoe T; Ohno R Br J Haematol; 2000 Jan; 108(1):90-2. PubMed ID: 10651729 [TBL] [Abstract][Full Text] [Related]
5. Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. Marks DC; Davey MW; Davey RA; Kidman AD Br J Haematol; 1993 May; 84(1):83-9. PubMed ID: 8101722 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272 [TBL] [Abstract][Full Text] [Related]
7. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A. Gollapudi S; Gupta S Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. Mickisch GH; Roehrich K; Koessig J; Forster S; Tschada RK; Alken PM J Urol; 1990 Sep; 144(3):755-9. PubMed ID: 1974934 [TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy. Månsson E; Paul A; Löfgren C; Ullberg K; Paul C; Eriksson S; Albertioni F Br J Haematol; 2001 Sep; 114(3):557-65. PubMed ID: 11552980 [TBL] [Abstract][Full Text] [Related]
11. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Zaman GJ; Lankelma J; van Tellingen O; Beijnen J; Dekker H; Paulusma C; Oude Elferink RP; Baas F; Borst P Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7690-4. PubMed ID: 7644478 [TBL] [Abstract][Full Text] [Related]
12. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells. Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942 [TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Marks DC; Davey MW; Davey RA; Kidman AD Biochem Pharmacol; 1995 Aug; 50(4):475-80. PubMed ID: 7646552 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. McGrath T; Latoud C; Arnold ST; Safa AR; Felsted RL; Center MS Biochem Pharmacol; 1989 Oct; 38(20):3611-9. PubMed ID: 2573357 [TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines. Seo T; Urasaki Y; Takemura H; Ueda T Anticancer Res; 2005; 25(2A):991-8. PubMed ID: 15868938 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156 [TBL] [Abstract][Full Text] [Related]